Stefano Fagiuoli

Publications (154) View all

• Article: Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.

  A Indriolo, S Fagiuoli, L Pasulo, G Fiorino, S Danese, P Ravelli
  Alimentary Pharmacology & Therapeutics 04/2013; 37(8):840-2. · 3.77 Impact Factor
• Article: An infrequent cause of colonic stenosis.

  S Greco, S Signorelli, A Indriolo, S Fagiuoli, P Ravelli
  [show abstract] [hide abstract]
  ABSTRACT: We present the case of a young woman with intestinal endometriosis, in which colonic stenosis unusually represents the clinical onset; diagnostic workup allows to highlight the role of gastrointestinal ultrasounds that suggest the nature of the stenosis.
  Arab Journal of Gastroenterology 12/2012; 13(4):186-7.
• Article: Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

  T Pressiani, C Boni, L Rimassa, R Labianca, S Fagiuoli, S Salvagni, D Ferrari, E Cortesi, C Porta, C Mucciarini, [......], F R Lutman, G Torzilli, M A Tommasini, R Ceriani, G Covini, M C Tronconi, L Giordano, N Locopo, S Naimo, A Santoro
  [show abstract] [hide abstract]
  ABSTRACT: Background Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B.Patients and methodsA consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.]ResultsOverall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar.Conclusion Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.
  Annals of Oncology 10/2012; · 6.43 Impact Factor
• Article: Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

  M Milan, S Boninsegna, L Scribano, S Lobello, S Fagiuoli, P Fabris, A Buda, D Martines
  [show abstract] [hide abstract]
  ABSTRACT: Pegylated interferon (PEG-IFN) and ribavirin is the most effective treatment for chronic hepatitis C virus (HCV) hepatitis, but the rate of sustained virological response (SVR) remains approximately 50%, and 15-20% of all treated patients have a virological relapse after completing the treatment. Studies on the SVR have failed to discriminate between non-responders and relapsers. To identify the risk factors for relapse among patients with an end-of-treatment response (ETR). We retrospectively analyzed 281 patients consecutively treated with PEG-IFN and ribavirin with a follow-up period of at least 24 weeks. The baseline details collected on each patient included demographic data, histological features, and biochemical profiles. Forty-six patients (16.4%) relapsed during the first 6 months of follow-up after discontinuing the therapy. Relapser patients were significantly older, had more steatosis, fibrosis, and showed significantly lower rapid virological response (RVR) rates compared with SVR patients. By logistic regression analysis, only the absence of RVR was found to be significantly associated with relapses in both subgroups of patients with genotypes 1 and 4 (p < 0.004) and those with genotypes 2 and 3 (p < 0.006). Severe fibrosis was also predictive of relapsing disease, but only for genotypes 2 and 3 patients (p < 0.003). During the treatment, serum HCV-RNA decreased more rapidly in patients with SVR compared to non-responder and relapser patients (p < 0.001). Interestingly, relapser patients exhibited an intermediate serum HCV-RNA decay during the first 4 weeks of therapy. Among HCV patients treated with PEG-IFN and ribavirin, the absence of RVR was the most important independent predictor of relapse, independent of the HCV genotype. In the subgroup of genotypes 2 and 3 patients, the severity of fibrosis was also an important factor associated with the relapse rate.
  Infection 11/2011; 40(2):173-9. · 2.66 Impact Factor
• Conference Proceeding: Trapianto in blocco di fegato-pancreas: esperienza iniziale del centro di Bergamo

  V. Corno, D. Pinelli, M. Zambelli, A. Aluffi, M. Guizzetti, G. Rota, A. Lucianetti, S. Fagiuoli, G. Remuzzi, R. Trevisan, M. Colledan
  XXXV Congresso Nazionale Società Italiana Trapianti d’Organo., Roma, Italy; 10/2011